Hythiam "buy"

01/10/08 - Brean Murray, Carret & Co

NEW YORK, January 10 (newratings.com) - Analysts at Brean Murray maintain their "buy" rating on Hythiam Inc (HYTM). The target price is set to $15.

In a research note published this morning, the analysts mention that the company’s robust momentum is expected to continue in 2008. The analysts expect Hythiam to announce at least one disease management partnership in the current quarter. The ITT analysis of several trials is expected to be reported in 1H08, Brean Murray says. The company has reported record PROMETA revenues for December, while announcing plans to cut operating expenses.